Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Phase 3 trial of elafibranor in PBC with inadequate response or intolerance to UDCA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Elafibranor received accelerated approval in 2024 as a second-line therapy for adults with PBC who have an inadequate response or intolerance to UDCA, based on results from the phase 3 ELATIVE trial demonstrating significant biochemical response and favorable tolerability, including no worsening of pruritus [50,51].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [50]
In the citing paper
“On the other hand, seladelpar (PPAR-δ selective) consistently improves pruritus and shows high biochemical response rates, while elafibranor (dual PPAR-α/δ) improves biochemical endpoints with a neutral pruritus effect but a reassuring safety signal overall [16,50].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [50]
In the citing paper
“Among patients with moderate-to-severe pruritus (44 in the elafibranor group and 22 in the placebo group), the least-squares mean change in WI-NRS score from baseline through week 52 did not differ significantly between the two groups.”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [50]
In the citing paper
“However, fibrosis-related endpoints such as transient elastography and non-invasive fibrosis scores were neutral in this trial.”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [50]
In the citing paper
“Normalization of ALP levels at week 52 occurred in 15% of patients receiving elafibranor and in none of the patients receiving placebo (p < 0.002) [50].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [50]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citationBerzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Self-citationA Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131
Self-citationRatziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Self-citationIncidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646
Self-citationA Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642
Self-citationThe 5-D itch scale: a new measure of pruritus
Elman, S., Hynan, L. S., Gabriel, V., & Mayo, M. J. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09586.x · Cited by 540
Self-citation
Cited by
Items 101–200 of 305
Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis
Schattenberg, J. M., Bañales, J. M., Hirschfield, G. M., Trivedi, P., Cable, E. E., McWherter, C. A., Billin, A. N., Crittenden, D. B., & Budas, G. R. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70598 · Cited by 5
Self-citationReview of Current and Upcoming Second-Line Treatments for Primary Biliary Cholangitis
Cumpian, N. A., Choi, G., & Saab, S. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08742-w · Cited by 6
Bile acids as therapeutic agents
Vu, B., Kawamoto, R., Villalba‐Davila, P., Dong, X., & Karnsakul, W. W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1732854 · Cited by 6
Ahmed, I. F., Rizwan, F., Mansoor, H., Fakhoury, M., Shaik, M. H., Gandhi, F. R., & Belletieri, C. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002672 · Cited by 7
van Hooff, M. C., de Veer, R. C., Werner, E., Beuers, U. H., Drenth, J. P. H., Cuperus, F. J. C., van Hoek, B., Veldt, B. J., Klemt‐Kropp, M., van Meer, S., et al. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003879 · Cited by 7
Managing pruritus in chronic liver disease: An in-depth narrative review
Marenco‐Flores, A., Sierra, L., Goyes, D., Kahan, T. F., Patwardhan, V. R., & Bonder, A. (2024) · Clinical Liver Disease · doi:10.1097/cld.0000000000000187 · Cited by 8
An update on novel investigational agents for the treatment of primary biliary cholangitis
Floreani, A., Gabbia, D., & Martin, S. D. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2573638 · Cited by 4
A comprehensive review of small molecule drugs approved by the FDA in 2024: Advance and prospect
Bai, Y., Duan, Q.-C., Seng, D., Xu, Y., Ren, H., Zhang, J., Shen, D., Yang, L., Liu, H., & Yuan, S. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.111025 · Cited by 5
Hepatic Nuclear Receptors in Cholestasis-to-Cholangiocarcinoma Pathology
Cheon, I., Kim, M., Kim, K. H., & Ko, S. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.07.023 · Cited by 7
Elafibranor: a breakthrough therapy revolutionizing primary biliary cholangitis (PBC) treatment
Gul, M. H., Waheed, A., Wardak, A. B., Shah, Y. R., Raja, H. A. A., Ilmaguook, B., Hussaini, H., & Zafar, F. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002794 · Cited by 4
Tanaka, A., Abe, M., Namisaki, T., Shimoda, S., Zeniya, M., Ido, A., Yoshiji, H., Ohira, H., Harada, K., Kakuda, Y., et al. (2025) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2025.100283 · Cited by 5
Tanaka, A., Treeprasertsuk, S., Chang, M., Tan, S.-S., Efe, C., Jeong, S., Ma, X., Weltman, M., Isayama, H., & Jia, J. (2025) · Hepatology International · doi:10.1007/s12072-025-10965-6 · Cited by 8
Reviewing novel findings and advances in diagnoses and treatment of primary biliary cholangitis
Floreani, A., Gabbia, D., & Martin, S. D. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2537192 · Cited by 4
Meta‐Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis
Martins, A., Khakoo, N. S., Corpechot, C., Rousseau, A., Reynolds, J. M., Kremer, A. E., Murad, M. H., Sultan, S., & Levy, C. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70634 · Cited by 5
Self-citationZaidi, M. H., Haider, Z., Sadia, F., Tayyab, M., Tariq, M., Ans, H., Javaid, M. B., Khan, A., Ahmad, M. H., Rasheed, R., et al. (2025) · JGH Open · doi:10.1002/jgh3.70196 · Cited by 4
Cheng, C., Hao, W., & Cheng, T. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i3.98783 · Cited by 4
Primary biliary cholangitis: current insights and novel therapies
Granito, A., Παππάς, Γ., Napoli, L., Stefanini, B., Tirotta, D., & Muratori, P. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2672493 · Cited by 10
Gadour, E., Miutescu, B. P., Bashir, H., Ali, A. A., Al-Anzi, S. K., Al-Shahrani, A., Almuhaidb, A., Mohamed, S., Abaalkhail, F. A., Kuriry, H., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050697 · Cited by 3
Levy, C., Bowlus, C. L., Lawitz, E., Antunes, N., Miller, B., Shu, J., Zein, C. O., & Kowdley, K. V. (2026) · Liver International · doi:10.1111/liv.70630 · Cited by 3
Self-citationIleal Bile Acid Transport Inhibitors for Cholestatic Pruritus: A Primer
Martins, A., & Levy, C. (2025) · Current Hepatology Reports · doi:10.1007/s11901-025-00699-2 · Cited by 4
Self-citationBhushan, S. R., & Kowdley, K. V. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001109 · Cited by 3
Self-citationFarhadi, S., Mohammadi, S., AlKindi, A. Y., & Al-Amri, I. S. (2025) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v16.i1.104535 · Cited by 5
Dean, R. D., Yazdanfar, M., Zepeda, J., Levy, C., Lammert, C. S., Pratt, D. S., Gordon, S. C., Forman, L., Assis, D. N., McGirr, A. A., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000703 · Cited by 7
Self-citationThe ethics of unlicensed therapy use in primary biliary cholangitis: a counter view
Jones, D. E. J., Mitchell-Thain, R., Culver, E. L., Dyson, J. K., Gish, R. G., Hansen, B. E., Hirschfield, G. M., Kowdley, K. V., Lleo, A., Kremer, A. E., et al. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01179-8 · Cited by 3
Self-citationPeverelle, M., Campbell, S. M.-A., Peverelle, J., Shah, S., Greener, K., Joshi, D., & Nayagam, J. S. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70666 · Cited by 7
Progress and prospects of gut microbiota-targeted therapy for primary biliary cholangitis
Tang, X. R., & You, X. (2025) · Gut Pathogens · doi:10.1186/s13099-025-00753-w · Cited by 4
Díaz‐González, Á., Molera, C., Gómez-Domínguez, E., Muñoz‐Bartolo, G., Ampuero, J., Fernández‐Rodríguez, C., Quintero, J., Molina, E., Salcedo, M., Olveira, A., et al. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2026.502629 · Cited by 3
Buechter, M., Manka, P. P., Bulut, K., Gerken, G., & Kahraman, A. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15030079 · Cited by 5
Gerussi, A., Sebode, M., Nofit, E., Stoelinga, A., Bernasconi, D. P., Leburgue, A., Invernizzi, P., Schramm, C., van Hoek, B., TINIAKOS, D. G., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001793 · Cited by 3
Self-citationZhang, S., Yu, J., Bai, S., Li, S. H., Qiu, Q., Kong, X., Xiang, C., Liu, Z., Yu, P., & Teng, Y. (2025) · Metabolites · doi:10.3390/metabo15050296 · Cited by 3
Liang, J., Gu, Y., Hu, L., Qu, H., Li, N., Xia, C., Feng, L., Li, Q., Hai, L., Yang, Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00994 · Cited by 5
Risk factors and prediction for DILI in clinical practice
Björnsson, H. K., & Bjornsson, E. S. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2468200 · Cited by 3
Per- and polyfluorinated active pharmaceutical ingredients: Overview and alternatives
Greinke, J., Mußler, P., Maack, G., Hug, M. J., Müller, M., & Speichert, G. (2026) · Sustainable Chemistry and Pharmacy · doi:10.1016/j.scp.2026.102416 · Cited by 8
Cançado, G. G. L., Chen, B., Cameron, M., Houri, I., Leung, K. K., Gulamhusein, A. F., Hansen, B. E., & Hirschfield, G. M. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000798 · Cited by 7
Gerussi, A., Nofit, E., Bernasconi, D. P., Kroll, C., Groß, F., Schregel, I., Marini, A., Cristoferi, L., Malinverno, F., Papp, M., et al. (2025) · United European Gastroenterology Journal · doi:10.1002/ueg2.70134 · Cited by 4
Self-citationPhase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis
Kowdley, K. V., Levy, C., & Jones, D. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2403986 · Cited by 3
Self-citationPhase II clinical trials in primary sclerosing cholangitis: Making the most of every opportunity?
Assis, D. N., & Hov, J. R. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.10.022 · Cited by 3
Aslam, M. N., Turgeon, D. K., Appelman, H. D., Stidham, R., McClintock, S. D., Allen, R., Moraga, G., Harber, I., Jencks, K. J., McNeely, M. M., et al. (2025) · medRxiv · doi:10.1101/2025.02.17.25322298 · Cited by 1
Elafibranor for primary biliary cholangitis: a dual PPAR agonist changing the treatment landscape
Abid, S., Ghaffar, S., Qaisar, A., Abid, H. B., Farhan, K., Akhtar, M., Eljack, M. M. F., & Goyal, A. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003395 · Cited by 2
Pan, S.-D., Xiong, C.-Y., Shen, Y.-J., Tian, J., Wang, Y., Wang, J., Wang, S., Li, F., Wang, L., Qiu, Q., et al. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i31.109828 · Cited by 2
Improving Primary Biliary Cholangitis Outcomes in the Evolving Landscape of Second‐Line Therapies
Scaravaglio, M., Ronca, V., Carbone, M., & Invernizzi, P. (2025) · Liver International · doi:10.1111/liv.70030 · Cited by 2
Self-citationRecent Advances in Primary Biliary Cholangitis Treatment
Das, T. S., & Vuppalanchi, R. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.06.008 · Cited by 3
Novel preclinical developments of the primary sclerosing cholangitis treatment landscape
Sohal, A., & Kowdley, K. V. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2330738 · Cited by 4
Self-citationEarly assessment of treatment response in primary biliary cholangitis: key to timely management
Koky, T., Dražilová, S., Janíčko, M., Toporcerová, D., Gazda, J., & Jarčuška, P. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04138-w · Cited by 7
Levy, C., Lleo, A., Martins, A., Scaravaglio, M., Bowlus, C. L., Carbone, M., Corpechot, C., Couto, C. A., Hansen, B. E., Hirschfield, G. M., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.03.038 · Cited by 14
Self-citationValidation of PBC‐10 in Japanese patients with primary biliary cholangitis
Takeuchi, A., Abe, M., Furukawa, S., Namisaki, T., Takahashi, A., Abe, K., Kikuchi, K., Miura, R., Tachizawa, N., Asaoka, Y., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14199 · Cited by 3
Prevalence and incidence of chronic kidney disease in patients with primary biliary cholangitis
Sousa, J. M., Rodríguez‐Tajes, S., Hernández‐Guerra, M., Casado, M., Berenguer, M., Castaño, Y. P., Morillas, R. M., García-Retortillo, M., García-Buey, L., Simón, M., et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02442-0 · Cited by 2
Popescu, I. R. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70948 · Cited by 3
Primary Biliary Cholangitis in 2025: A New Frontier
Klatzkow, H. R., Bhavsar‐Burke, I., Pearson, M. M., & Wentworth, B. J. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003559 · Cited by 2
Tang, G., Zhang, J., Zhang, L., Xia, L., Tang, X., Chen, R., & Zhou, R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1432814 · Cited by 3
Pruritus, Fatigue, Osteoporosis and Dyslipoproteinemia in Pbc Patients: A Clinician’s Perspective
Dražilová, S., Koky, T., Macej, M., Janíčko, M., Simkova, D., Tsedendamba, A., Комарова, С. Г., & Jarčuška, P. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15020030 · Cited by 4
Maxwell, M., Deng, Y., Chen, B., Silveira, M. G., Boyer, J. L., & Assis, D. N. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70574 · Cited by 3
Elafibranor in primary biliary cholangitis
(2023) · doi:10.1038/s41575-023-00878-w · Cited by 2
Gordon, S. C., Villamil, A., Jacobson, I. M., Lawitz, E., Younes, Z. H., Silveira, M. G., Bowlus, C. L., Drenth, J. P. H., Vierling, J. M., Morgera, U., et al. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000918 · Cited by 3
Self-citationSong, J., Wang, Y., Guo, R., Wang, K. Y., Hu, Y., Cui, M., Wang, G., Hao, H., Wang, H., & Xu, X. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178910 · Cited by 3
Passos, P. R. C., Filho, V. O. C., Noronha, M. M., Rossi, Y. I., Vitor, I. C., Tomé, M. R., Amador, W. F. O., Silveira, I. B., Leite, M. D. A. B. C., Motta, R. V., et al. (2025) · American Journal of Transplantation · doi:10.1016/j.ajt.2025.10.009 · Cited by 2
Pellegrini, P., Gelbrich, T., Štefinović, M., Nerdinger, S., & Braun, D. E. (2025) · Crystal Growth & Design · doi:10.1021/acs.cgd.5c00844 · Cited by 2
Liu, Y., Chen, L., Hao, W., Zhao, K., & Li, C. (2025) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320251327621 · Cited by 3
Mohamed Anasdeen, S., Shahinaz, S., & Vijayakumar, T. M. (2024) · Cureus · doi:10.7759/cureus.67151 · Cited by 5
Sebode, M., Bantel, H., Baumann, U., Bufler, P., Demir, M., Dold, L., Keitel, V., Klein, R., Kremer, A. E., Jansen, P. L., et al. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2769-2475 · Cited by 2
Gerussi, A., & Fornai, M. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108144 · Cited by 2
Yang, Y., Ma, X., Zhou, C., Xu, N., Ding, D., Ma, Z., Zhou, L., & Cui, P. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i30.6391 · Cited by 1
“Overlap” Syndromes in Autoimmune Liver Disease
Tzadok, R., & Houri, I. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.04.008 · Cited by 1
Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis
Pham, H. N., Pham, L., & Sato, K. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2362263 · Cited by 1
Jones, D. E., Combe, E., Knight, H., Laskier-Owens, V., Ren, S., Wright, T., Boing, E., & Pashley, A. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0206 · Cited by 1
Self-citationElafibranor: A promising treatment for alcohol-associated liver disease?
Wei, H., Sang, L.-X., & Chang, B. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i39.4313 · Cited by 1
Stein, K., Hofmann, W. P., Franke, A., Petroff, D., Müller, T., Bantel, H., Günther, R., Denk, G., Reuken, P. A., Schattenberg, J. M., et al. (2025) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2721-1160 · Cited by 1
Self-citationSilveira, I. B., Rezende, R. A. A., Neto, C. A. M. L., Rossi, Y. I., Leite, M. D. A. B. C., & Cançado, G. G. L. (2025) · Gastroenterology Insights · doi:10.3390/gastroent16030030 · Cited by 1
Kugiyama, Y., Abe, M., Namisaki, T., Yoshiji, H., Abe, K., Ohira, H., Shirahashi, R., Yokoyama, K., Fukunaga, A., Kawata, K., et al. (2025) · Hepatology Research · doi:10.1111/hepr.70035 · Cited by 1
Okoruwa, E. T., & Mayo, M. J. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.04.010 · Cited by 1
Self-citationOptimizing Care in Primary Biliary Cholangitis: Current Treatments and the Second-Line Decision
Choi, G., Jesudian, A. B., & Saab, S. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09537-3 · Cited by 4
Oral administration of Lactobacillus rhamnosus MP108 ameliorates hemolytic jaundice in rats
Wu, G., Ai, Q., & Shi, Y. (2025) · Journal of Food Science · doi:10.1111/1750-3841.17671 · Cited by 1
Russo, M. W. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09177-7 · Cited by 1
Elafibranor in the treatment of primary biliary cholangitis
Ergenç, İ., & Heneghan, M. A. (2025) · Future Rare Diseases · doi:10.1080/23995270.2025.2580910 · Cited by 2
Self-citationEmerging Therapeutics for Primary Biliary Cholangitis
Cho, E. J. (2025) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2025.045 · Cited by 1
Martins, A., & Levy, C. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001076 · Cited by 3
Self-citationImplementation of a care bundle improves PBC management
Smith, R., Burke, L., Abbas, N., Aspinall, R., Thorburn, D., Heneghan, M. A., Yeoman, A. D., Leithead, J., Braniff, C., Mitchell-Thain, R., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101422 · Cited by 3
Self-citationHuang, Z., Zhang, M., Zhang, X., Ge, Y., He, C., & Li, J. (2026) · Biomedicines · doi:10.3390/biomedicines14051101 · Cited by 1
Primary Biliary Cholangitis: Updates in Management and Goals of Treatment
Carlson, K., Salge, M. H., & Cholankeril, G. T. (2024) · Current Hepatology Reports · doi:10.1007/s11901-024-00667-2 · Cited by 1
The role of the PPAR system in diabetic cardiovascular risk and beyond
Ruscica, M., Macchi, C., Corsini, A., & Sirtori, C. R. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000943 · Cited by 1
Recompensation in Cirrhosis: Biomarkers and Strategies
Ramírez-Quesada, W. E., Alvarado‐Tápias, E., Shalaby, S., & Hernández–Gea, V. (2025) · Seminars in Liver Disease · doi:10.1055/a-2542-9930 · Cited by 2
Editorial: UDCA Dosing in PBC – Between Guideline Adherence and Clinical Reality
Hernández-Évole, H., & Londoño, M. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70703 · Cited by 1
Autoimmune und genetisch-cholestatische Lebererkrankungen: die neuen Leitlinien
Sebode, M., Hudert, C. A., Lohse, A. W., & Bufler, P. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2462-8656 · Cited by 2
Year in Review: Selection of Best Papers in Gastroenterology and Hepatology 2024
Camilleri, M., & Dellon, E. S. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.06.001 · Cited by 1
Lessons From COBALT: Will the Bell Also Toll for Thee?
Vierling, J. M., & Pockros, P. J. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003061 · Cited by 1
Self-citationLakshmanan, V., & Morris, L. (2025) · Cureus · doi:10.7759/cureus.94172 · Cited by 3
Ruiu, A., Calabrese, M. P., Meschisi, P., Plebani, R., Maria, B., Lleò, A., & Ronca, V. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106883 · Cited by 1
Bile acid signaling: from dynamic pool composition to inter-organ communication
Yang, F., Wei, T., Liu, K. L., Chu, H., & Yang, L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1890710 · Cited by 3
Romeo, M., Nardo, F. D., Basile, C., Napolitano, C., Vaia, P., Martinelli, G., Gregorio, A. D., Puorto, L. D., Indipendente, M., Dallio, M., et al. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15120597 · Cited by 3
Liver disease and general anesthesia: what the anesthesiologist needs to know
Flick, M., Sebode, M., Eichlseder, M., & Saugel, B. (2026) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001648 · Cited by 1
Giorgio, C. D., Urbani, G., Massa, C., Marchianò, S., Biagioli, M., Bordoni, M., Lachi, G., Sensini, B., SORDO, R. D., Paniconi, F., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000779 · Cited by 1
Novel intervention for alcohol-associated liver disease
Gao, F.-Q., Zhu, J., & Feng, X. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i39.4308 · Cited by 1
Liao, W., Fu, S., Yang, A., & Yang, Y. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251370111 · Cited by 2
Yu, J., Wang, J., Li, S. H., Bai, S., Wang, X., Ban, Y., Zhang, S., Yu, Y., Liu, J., Liu, Z., et al. (2026) · Journal of Biological Engineering · doi:10.1186/s13036-026-00627-y · Cited by 2
(2026) · doi:10.3389/fphar.2026.1769883 · Cited by 1
Liao, W., Fu, S., Yang, A., & Yang, Y. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4863938 · Cited by 1
Upadacitinib for refractory primary biliary cholangitis
Kolev, M., Möller, B., Berzigotti, A., & Semmo, N. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.004 · Cited by 1
Recent advances in diagnosis and management of chronic cholestatic liver diseases: expert consensus
Mukewar, S. V. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20250288 · Cited by 1
Metadata
- Authors
- Kowdley, K. V., Bowlus, C. L., Levy, C., Akarca, U. S., Alvares-da-Silva, M. R., Andreone, P., Arrese, M., Corpechot, C., Francque, S. M., Heneghan, M. A., Invernizzi, P., Jones, D., Kruger, F. C., Lawitz, E., Mayo, M. J., Shiffman, M. L., Swain, M. G., Valera, J. M., Vargas, V., Vierling, J. M., Villamil, A., Addy, C., Dietrich, J., Germain, J.-M., Mazain, S., Rafailovic, D., Taddé, B., Miller, B., Shu, J., Zein, C. O., & Schattenberg, J. M.
- Affiliations
- Universidade Federal do Rio Grande (BR)
- From Liver Institute Northwest, Seattle (K.V.K.); the Division of Gastroenterology and Hepatology, UC Davis School of Medicine, Sacramento (C.L.B.); Schiff Center for Liver Diseases, University of Miami, Miami (C.L.); the Department of Gastroenterology, Ege University Faculty of Medicine, İzmir, Turkey (U.S.A.); Gastroenterology and Hepatology Division, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil (M.R.A.-S.); Medicina Interna Metabolica, Baggiovara Hospital, Azienda Ospedaliero-Universitaria di Modena and Università di Modena e Reggio Emilia, Modena (P.A.), and the Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, and the European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Fondazione IRCCS San Gerardo dei Tintori, Monza (P.I.) — all in Italy; Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago ...
- ORCID
- Kowdley, Kris V.
- Bowlus, Christopher L.
- Levy, Cynthia
- Akarca, Ulus S.
- Arrese, Marco
- Corpechot, Christophe
- Francque, Sven M.
- Heneghan, Michael A.
- Invernizzi, Pietro
- Jones, David
- Lawitz, Eric
- Mayo, Marlyn J.
- Shiffman, Mitchell L.
- Swain, Mark G.
- Vierling, John M.
- Villamil, Alejandra
- Addy, Carol
- Dietrich, Julie
- Rafailovic, Dragutin
- Schattenberg, Jörn M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-02-29
- Volume
- 390
- Issue
- 9
- Pages
- 795-805
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388621682
- Semantic Scholar
- 737ff94dc0523a82fdfc3a80f921364b42703d37
- Cited by
- 314
- References
- 33
- Citations by year
- 2026: 112 · 2025: 125 · 2024: 76
- FWCI
- 52.53
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Ipsen
- GENFIT
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- elafibranor, primary biliary cirrhosis, ursodeoxycholic acid, cholestasis, alkaline phosphatase, pruritus, liver fibrosis, treatment efficacy, drug safety, bile duct destruction, cholestatic liver disease
- MeSH terms
- Administration, Oral, Alkaline Phosphatase, Bilirubin, Cholagogues and Choleretics, Cholestasis, Double-Blind Method, Gastrointestinal Agents, Humans, Liver Cirrhosis, Biliary, Propionates, Pruritus, Ursodeoxycholic Acid, Treatment Outcome, Chalcones, Peroxisome Proliferator-Activated Receptors, PPAR alpha, PPAR delta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.